Guide

What to consider when building a channel strategy for a rare disease product

A checklist for biopharma companies

Evaluating channel strategy options for a rare disease product is an essential element of commercialization. Biopharma companies should ask themselves these five questions to ensure their novel therapy reaches the right patients at the right time.

Enter your information below to download the checklist. 

Pardot Form

Related resources

Article

AI-powered tools for pricing: Key takeaways from ISPOR Europe 2025

Article

Rethinking oncology launches: How the next generation of patients is reshaping strategies

Newsletter

HTA Quarterly Spring 2026